Immunic (IMUX) Change in Accured Expenses (2013 - 2026)

Immunic (IMUX) has 14 years of Change in Accured Expenses data on file, last reported at $273000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 94.21% year-over-year to $273000.0; the trailing twelve-month figure through Mar 2026 stood at -$4.6 million (down 177.5% YoY), and the FY2025 full-year result was -$209000.0, up 95.7% from the prior year.
• Change in Accured Expenses improved to $273000.0 in Q1 2026, from $16000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.7 million in Q1 2025 to a low of -$6.1 million in Q1 2024.
• A 5-year average of -$283764.7 and a median of $12000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 645.92% in 2023 and plunged 24766.67% in 2024, its largest moves.
• Tracing IMUX's Change in Accured Expenses over 5 years: stood at -$589000.0 in 2022, then surged by 102.04% to $12000.0 in 2023, then sank by 24766.67% to -$3.0 million in 2024, then jumped by 100.54% to $16000.0 in 2025, then surged by 1606.25% to $273000.0 in 2026.
• Business Quant data shows IMUX's Change in Accured Expenses at $273000.0 in Q1 2026, $16000.0 in Q4 2025, and $6000.0 in Q3 2025.